223 related articles for article (PubMed ID: 31687649)
1. Effect of Bisphosphonates on Function and Mobility Among Children With Osteogenesis Imperfecta: A Systematic Review.
Constantino CS; Krzak JJ; Fial AV; Kruger KM; Rammer JR; Radmanovic K; Smith PA; Harris GF
JBMR Plus; 2019 Oct; 3(10):e10216. PubMed ID: 31687649
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review.
Rijks EB; Bongers BC; Vlemmix MJ; Boot AM; van Dijk AT; Sakkers RJ; van Brussel M
Horm Res Paediatr; 2015; 84(1):26-42. PubMed ID: 26021524
[TBL] [Abstract][Full Text] [Related]
6. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
Sridharan K; Sivaramakrishnan G
Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
8. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
10. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Beecham E; Candy B; Howard R; McCulloch R; Laddie J; Rees H; Vickerstaff V; Bluebond-Langner M; Jones L
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010750. PubMed ID: 25768935
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate therapy for osteogenesis imperfecta.
Phillipi CA; Remmington T; Steiner RD
Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
[TBL] [Abstract][Full Text] [Related]
13. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
[TBL] [Abstract][Full Text] [Related]
14. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.
Ying ZM; Hu B; Yan SG
Orthop Surg; 2020 Aug; 12(4):1293-1303. PubMed ID: 32589343
[TBL] [Abstract][Full Text] [Related]
15. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
Dimeglio LA; Ford L; McClintock C; Peacock M
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):43-53. PubMed ID: 15679068
[TBL] [Abstract][Full Text] [Related]
16. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
Hald JD; Evangelou E; Langdahl BL; Ralston SH
J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]